| __timestamp | Incyte Corporation | Sarepta Therapeutics, Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 347523000 | 94231000 |
| Thursday, January 1, 2015 | 479514000 | 146394000 |
| Friday, January 1, 2016 | 581861000 | 188272000 |
| Sunday, January 1, 2017 | 1326361000 | 166707000 |
| Monday, January 1, 2018 | 1197957000 | 401843000 |
| Tuesday, January 1, 2019 | 1154111000 | 560909000 |
| Wednesday, January 1, 2020 | 2215942000 | 722343000 |
| Friday, January 1, 2021 | 1458179000 | 771182000 |
| Saturday, January 1, 2022 | 1585936000 | 877090000 |
| Sunday, January 1, 2023 | 1627594000 | 877387000 |
| Monday, January 1, 2024 | 2606848000 |
Cracking the code
In the competitive world of biotechnology, research and development (R&D) spending is a key indicator of a company's commitment to innovation. Over the past decade, Incyte Corporation and Sarepta Therapeutics, Inc. have demonstrated contrasting approaches to R&D investment. From 2014 to 2023, Incyte's R&D expenses surged by over 360%, peaking in 2020 with a remarkable 2.2 billion dollars. This aggressive investment strategy underscores Incyte's dedication to pioneering new treatments. Meanwhile, Sarepta's R&D spending grew by approximately 830% during the same period, reflecting its focused efforts on developing groundbreaking therapies. Notably, Sarepta's R&D expenses consistently increased, reaching nearly 880 million dollars by 2023. This data highlights the dynamic nature of biotech innovation, where strategic R&D investments can drive significant advancements in medical science.
R&D Spending Showdown: Novartis AG vs Sarepta Therapeutics, Inc.
Analyzing R&D Budgets: Genmab A/S vs Incyte Corporation
Incyte Corporation or Sarepta Therapeutics, Inc.: Who Leads in Yearly Revenue?
Research and Development Expenses Breakdown: Incyte Corporation vs Ascendis Pharma A/S
Incyte Corporation vs Viking Therapeutics, Inc.: Strategic Focus on R&D Spending
Who Prioritizes Innovation? R&D Spending Compared for Incyte Corporation and Veracyte, Inc.
Incyte Corporation or HUTCHMED (China) Limited: Who Invests More in Innovation?
Research and Development: Comparing Key Metrics for Incyte Corporation and Viridian Therapeutics, Inc.
Analyzing R&D Budgets: Intra-Cellular Therapies, Inc. vs Sarepta Therapeutics, Inc.
Analyzing R&D Budgets: Dr. Reddy's Laboratories Limited vs Sarepta Therapeutics, Inc.
R&D Spending Showdown: Sarepta Therapeutics, Inc. vs Iovance Biotherapeutics, Inc.
Comparing Innovation Spending: Sarepta Therapeutics, Inc. and Mesoblast Limited